

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

AMLOT ET AL.

APPLICATION NO: NOT YET KNOWN

FILED: HEREWITH

FOR: USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF
RHEUMATOID ARTHRITIS OR SKIN DISEASES

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above-identified application as follows:

IN THE SPECIFICATION

Page 1, line 1, insert a case lineage paragraph as follows:

-- This application is a continuation of International Application No. PCT/EP99/05316
filed July 26, 1999. --

IN THE CLAIMS

Cancel claim 7.

Claim 8, line 1, replace "anyone of claims 4 to 6" with -- claim 4 --.

Claim 9, line 1, delete "or 2,".

Claim 10, line 1, delete "or 7,".

Add new claim 11:

(new) 11. A pharmaceutical composition comprising a CD25 binding molecule according to
claim 1 and an agent effective in treating rheumatoid arthritis or inflammatory or
hyperproliferative skin diseases.

RECEIVED 01/25/01

REMARKS


A reference to the parent application, PCT/EP99/05316 filed July 26, 1999, has been inserted in the specification.

The claims have been amended to remove multiple dependencies.

Claim 7 has been cancelled and replaced by new claim 11.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6924



Diane E. Furman
Attorney for Applicants
Reg. No. 31,104

Date: January 25, 2001